GLAUKOS: Peers

The FY2025 (Dec) proxy of GLAUKOS names 21 peer companies for pay. Among GLAUKOS and these peers, CEO pay was 4th highest of 6 and total shareholder return was 4th highest of 6.

4th highest of 6in GLAUKOS and its pay peers, FY2025 (Dec) by CEO pay:

$6.1M$15.0M

4th highest of 6in GLAUKOS and its pay peers, FY2025 (Dec) by total shareholder return:

$86$611

Pay peer group, FY2025 (Dec) proxy

Natera
INSMED
Ionis Pharmaceuticals
TransMedics Group
Repligen
Apellis PharmaceuticalsNot disclosedNot disclosed
AxonicsNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
BridgeBio PharmaceuticalsNot disclosedNot disclosed
CONMEDNot disclosedNot disclosed
Exact SciencesNot disclosedNot disclosed
HaemoneticsNot disclosedNot disclosed
HalozymeNot disclosedNot disclosed
Inari MedicalNot disclosedNot disclosed
Inspire MedicalNot disclosedNot disclosed
Intra-CellularNot disclosedNot disclosed
Lantheus HoldingsNot disclosedNot disclosed
STAAR SurgicalNot disclosedNot disclosed
Ultragenyx PharmaceuticalsNot disclosedNot disclosed
VericelNot disclosedNot disclosed
iRhythm TechnologiesNot disclosedNot disclosed
21 companies

Changes by year

FY2025 (Dec) proxy

  • AddedBlueprint Medicinespay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedBridgeBio Pharmaceuticalspay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedExact Sciencespay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedHalozymepay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedInari Medicalpay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedIntra-Cellular Therapeuticspay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedIonis Pharmaceuticalspay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedNaterapay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedRepligenpay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • AddedTransMedics Grouppay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • RemovedAtriCurepay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • RemovedCatalyst Pharmapay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • RemovedFulgent Geneticspay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • RemovedNevropay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • RemovedNuVasivepay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)
  • RemovedTravere Therapeuticspay peer groupFor the 2025 Peer Group, six peer companies used for 2024 pay decisions that no longer met the size criteria were removed (AtriCure, Catalyst Pharma, Fulgent Genetics, Nevro, NuVasive, and Travere Therapeutics) and replaced with ten companies (Blueprint Medicines, BridgeBio Pharmaceuticals, Exact Sciences, Halozyme, Intra-Cellular Therapeutics, Ionis Pharmaceuticals, Inari Medical, Natera, Repligen, and TransMedics Group)

FY2024 (Dec) proxy

  • AddedCatalyst Pharmapay peer group
  • AddedINSMEDpay peer group
  • AddedSTAAR Surgicalpay peer group
  • AddedTravere Therapeuticspay peer group
  • RemovedAerie Pharmaceuticalspay peer group
  • RemovedArtivionpay peer group
  • RemovedCardiovascular Systemspay peer group
  • RemovedCare DXpay peer group
  • RemovedICU Medicalpay peer group
  • RemovedIntegra Life Sciencespay peer group
  • RemovedInvitaepay peer group

FY2023 (Dec) proxy

  • AddedAxonicspay peer group
  • AddedCareDxpay peer group
  • AddedFulgent Geneticspay peer group
  • AddedLantheus Holdingspay peer group
  • AddedVericelpay peer group
  • RemovedGlobus Medicalpay peer group
  • RemovedInsuletpay peer group
  • RemovedMasimopay peer group
  • RemovedNaterapay peer group
  • RemovedRepligenpay peer group
  • RemovedTandem Diabetespay peer group

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.